Genmab | GEN - Ativo Circulante





Ativo Circulante Alterar Data
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Almirall EUR 713.98M 69K 2025-12
Amarin USD 626.02M 23.87M 2026-03
Amgen USD 31.48B 2.42B 2026-03
argenx SE USD 6.9B 1.07B 2025-12
AstraZeneca USD 29.61B 890M 2026-03
Bayer EUR 35.3B 2.39B 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Demant DKK 10.08B 128M 2025-12
Exelixis USD 1.21B 234.65M 2026-03
Fresenius Medical Care EUR 8.11B 209.55M 2026-03
Genmab DKK 2.88B 1.59B 2025-12
GlaxoSmithKline GBP 17.76B 251M 2026-03
GN Store Nord DKK 4.85B 3.79B 2026-03
GRIFOLS EUR 5.25B 180M 2026-03
Hikma Pharmaceutical USD 2.64B 86M 2025-12
Insmed USD 1.61B 181.04M 2026-03
Lakefront Biotherapeutics EUR 3.06B 18.72M 2026-03
Lonza CHF 8B 3.41B 2025-12
Merck EUR 14.16B 932M 2026-03
Novartis USD 26.61B 3.85B 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sanofi EUR 30.16B 789M 2026-03
UCB EUR 6.05B 733M 2025-12